MD First Research | Chandler, AZ

Research site

(Unclaimed)

Location

3190 S Gilbert Road, Suite 5, Chandler, Arizona, United States of America

Site insights

Top conditions

Top treatments

ABP-450

Simufilam

AVP-786

Deudextromethorphan Hydrobromide

Ofatumumab

Droxidopa

Remternetug

Rimegepant

Zavegepant

LY3502970

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 20 total trials

A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)

This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptom...

Active, not recruiting

Alzheimer's Disease

Mental Disorders

Drug: Placebo

Drug: Donanemab

A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor (ACHIEVE-5)

The main purpose of this study is to determine the safety and efficacy of orforglipron. Participants will have Type 2 Diabetes (T2D) and have inadequ...

Enrolling

Type 2 Diabetes

Drug: Orforglipron

Drug: Placebo

A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)

The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early symptomatic A...

Active, not recruiting

Alzheimer's Disease

Drug: Remternetug (SC)

Drug: Placebo

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

This is a Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of KarXT in male and female...

Enrolling

Psychosis Associated With Alzheimer's Disease

Drug: Placebo

Drug: KarXT

Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy

The purpose of this study is to evaluate how safe and how well a treatment works compared to placebo for people with nerve pain that begins in their...

Not yet enrolling

Distal Sensory Polyneuropathy

Neuropathic Pain

Drug: Placebo

Drug: LY3848575

Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

This is an extension study of the Phase 3 Studies 15-AVP-786-301, 15-AVP-786-302, and 17-AVP-786-305, which also allows participants from the Phase 2...

Active, not recruiting

Agitation in Patients With Dementia of the Alzheimer's Type

Drug: AVP-786

Open-label Extension for Phase 3 Clinical Trials of Simufilam

The goal of this open-label extension study is to assess long-term safety and tolerability of simufilam 100 mg in subjects who have completed the RET...

Invitation-only

Alzheimer Disease

Drug: Simufilam

Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls. (AGNOS)

This study will evaluate the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early in the course of...

Active, not recruiting

Relapse Remitting Multiple Sclerosis

Drug: Ofatumumab

Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease (TargetTau-1)

The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants...

Enrolling

Alzheimer Disease, Early Onset

Other: Placebo

Drug: BMS-986446